CFA
BCRX icon

Cahill Financial Advisors’s BioCryst Pharmaceuticals BCRX Stock Holding History

Cahill Financial Advisors’s Portfolio BCRX Stock Details BCRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-3,300
Closed -$47K – 277
2021
Q3 		$47K Buy
+3,300
New +$52K 0.01% 345

Other funds holding BCRX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
PAMS
Pictet Asset Management (Switzerland) Geneva 73, Switzerland $84.3B AUM 26.5% 1-Year Est. Return
Fisher Asset Management
Fisher Asset Management Camas, Washington $295B AUM 31.6% 1-Year Est. Return
SCM
Sarissa Capital Management Greenwich, Connecticut $158M AUM 103.7% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
RM
RP Management New York $139M AUM 37.98% 1-Year Est. Return

Cahill Financial Advisors's BCRX Position: Q4 2021 in Review

Cahill Financial Advisors sold out of BioCryst Pharmaceuticals (BCRX) in Q4 2021, closing a stake of 3,300 shares — an estimated $47K sold.

Cahill Financial Advisors first reported a position in BCRX in Q3 2021 and held it in 1 quarter. The position peaked at $47K in Q3 2021. 206 funds tracked by Wall St. Rank hold BCRX as of Q4 2021.

  • Cahill Financial Advisors reported no remaining BioCryst Pharmaceuticals position as of Q4 2021 after selling out during the quarter.
  • Cahill Financial Advisors sold 3,300 BioCryst Pharmaceuticals shares in Q4 2021, an estimated $47K.
  • Cahill Financial Advisors first reported a position in BioCryst Pharmaceuticals in Q3 2021 and held it in 1 quarter.
  • Cahill Financial Advisors's BioCryst Pharmaceuticals position peaked at $47K in Q3 2021.
  • 206 funds tracked by Wall St. Rank held BioCryst Pharmaceuticals as of Q4 2021.

Based on Cahill Financial Advisors's 13F filing for Q4 2021, filed 11 Feb 2022.